These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3803417)

  • 21. Resolution of nicotinic acid-induced acanthosis nigricans by substitution of an analogue (acipimox) in a patient with type V hyperlipidaemia.
    Coates P; Shuttleworth D; Rees A
    Br J Dermatol; 1992 Apr; 126(4):412-4. PubMed ID: 1571266
    [No Abstract]   [Full Text] [Related]  

  • 22. A comparison between nicotinic acid and acipimox in hypertriglyceridaemia--effects on serum lipids, lipoproteins, glucose tolerance and tolerability.
    Tornvall P; Walldius G
    J Intern Med; 1991 Nov; 230(5):415-21. PubMed ID: 1940776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Acipimox (Olbetam) as a secondary hypolipemic agent in combined hypertriglyceridemia and hyperlipidemia].
    Yeshurun D; Hamood H; Morad N; Naschitz J
    Harefuah; 2000 Apr; 138(8):650-3, 710. PubMed ID: 10883206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover.
    Seed M; O'Connor B; Perombelon N; O'Donnell M; Reaveley D; Knight BL
    Atherosclerosis; 1993 Jun; 101(1):61-8. PubMed ID: 8216503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes.
    Paolisso G; Tagliamonte MR; Rizzo MR; Gualdiero P; Saccomanno F; Gambardella A; Giugliano D; D'Onofrio F; Howard BV
    Diabetologia; 1998 Oct; 41(10):1127-32. PubMed ID: 9794097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improvement of lipoprotein lipid composition in type II diabetic patients with concomitant hyperlipoproteinemia by acipimox treatment. Results of a multicenter trial.
    Koev D; Zlateva S; Susic M; Babic D; Profozic V; Skrabalo Z; Langrová H; Cvrkalová AL; Rajecová E; Klimes I
    Diabetes Care; 1993 Sep; 16(9):1285-90. PubMed ID: 8404433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
    Stuyt PM; Stalenhoef AF; Demacker PN; Van 't Laar A
    Atherosclerosis; 1985 Apr; 55(1):51-62. PubMed ID: 3924065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Acipimox in primary hyperlipidemias: safety and efficacy evaluated in six months].
    Davidoff P; Ruiz F; Varas MA; García de los Ríos M; Silva MA; González G; Tapia JC
    Rev Med Chil; 1991 Oct; 119(10):1140-6. PubMed ID: 1845208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharma clinics. Drug of the month. Acipimox (Olbetam)].
    Scheen AJ
    Rev Med Liege; 1995 Nov; 50(11):489-90. PubMed ID: 8532997
    [No Abstract]   [Full Text] [Related]  

  • 30. Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM.
    Saloranta C; Taskinen MR; Widen E; Härkönen M; Melander A; Groop L
    Diabetes; 1993 Nov; 42(11):1559-66. PubMed ID: 8405695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
    Bajaj M; Suraamornkul S; Romanelli A; Cline GW; Mandarino LJ; Shulman GI; DeFronzo RA
    Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Acipimox treatment of hyperlipidemia type II].
    Noseda G; Fragiacomo C; Cairoli R
    Schweiz Med Wochenschr; 1982 Dec; 112(49):1790-1. PubMed ID: 6758114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid-lowering effect and safety of acipimox in hemodialysis patients and renal transplant recipients.
    Tzanatos H; Koutsikos D; Agroyannis B; Kapetanaki A; Tsoutsos D; Konstadinidou I; Chondros K; Exarchos D
    Ren Fail; 1994; 16(3):391-405. PubMed ID: 8059022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The reduction in postprandial lipemia after exercise is independent of the relative contributions of fat and carbohydrate to energy metabolism during exercise.
    Malkova D; Hardman AE; Bowness RJ; Macdonald IA
    Metabolism; 1999 Feb; 48(2):245-51. PubMed ID: 10024090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of a phase IV study carried out with acipimox in type II diabetic patients with concomitant hyperlipoproteinaemia.
    Lavezzari M; Milanesi G; Oggioni E; Pamparana F
    J Int Med Res; 1989; 17(4):373-80. PubMed ID: 2676653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.
    Durrington PN; Bhatnagar D; Mackness MI; Morgan J; Julier K; Khan MA; France M
    Heart; 2001 May; 85(5):544-8. PubMed ID: 11303007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial.
    Makimura H; Stanley TL; Suresh C; De Sousa-Coelho AL; Frontera WR; Syu S; Braun LR; Looby SE; Feldpausch MN; Torriani M; Lee H; Patti ME; Grinspoon SK
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1123-33. PubMed ID: 26691888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults.
    Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5813-8. PubMed ID: 11739444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
    Pontiroli AE; Manzoni MF; Malighetti ME; Lanzi R
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution.
    Hadigan C; Rabe J; Meininger G; Aliabadi N; Breu J; Grinspoon S
    Am J Clin Nutr; 2003 Feb; 77(2):490-4. PubMed ID: 12540412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.